Trial intelligence / Profile preview

Polypodium Leucotomos for Skin Cancer Prevention

NCT02813902Phase 1Withdrawn

Sponsor: Massachusetts General Hospital
Start: Jul 2019
Primary completion: May 2020

Overview

Phase 1, randomised, double-blind trial in actinic keratosis (AK) and skin cancer, sponsored by Massachusetts General Hospital. Primary endpoint: Total number of new clinically visible actinic keratoses at 1 year. Planned start Jul 2019; status: withdrawn.

Conditions

actinic keratosis (AK)skin cancer

Beyond the preview

Go deeper on NCT02813902.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02813902.